Trigeminal Neuralgia
Trigeminal neuralgia is a chronic pain condition affecting the trigeminal nerve, which carries sensation from the face to the brain. It causes sudden, severe, shock-like or stabbing facial pain that can be triggered by everyday activities such as eating, talking, or even a light breeze. Often called the 'suicide disease' due to the intensity of the pain, trigeminal neuralgia most commonly affects people over 50 and is more prevalent in women.
Last updated November 10, 2026
Understanding Trigeminal Neuralgia
Trigeminal neuralgia (TN) is a disorder of the fifth cranial nerve that produces brief, electric-shock-like pain in one side of the face, set off by harmless touch such as chewing, talking, brushing teeth, shaving or a breeze. It is uncommon, with 4 to 13 new cases per 100,000 people a year and perhaps 1 adult in 1,000 affected at any time, and women outnumber men by about 1.5 to 1. Onset peaks in the 50s and 60s; onset before 40 should prompt a search for multiple sclerosis, which accounts for 2 to 4 percent of cases, or a tumor at the base of the skull. The pain usually sits in the cheek and jaw (the second and third divisions of the nerve) and only rarely in the forehead. About half of patients also have a duller continuous background ache between attacks, a subtype now called TN with concomitant continuous pain that responds somewhat less well to treatment.
In most people the cause is a small artery, usually the superior cerebellar artery, pressing on the trigeminal nerve root where it enters the brainstem. Decades of pulsation wear away the myelin at that spot so that touch fibers short-circuit into pain fibers, a signal that then recruits hyperexcitable neurons and fires off as a volley. This 'ignition' explains the hallmark features: a light trigger, an explosive attack lasting seconds to 2 minutes, and a refractory period afterward when the face briefly cannot be set off again. High-resolution MRI shows such contact in about 80 percent of classical cases; when no cause is found it is labeled idiopathic, and when MS plaques or a tumor are responsible it is secondary. The natural course is of attack clusters lasting weeks to months followed by remissions that can last years, but remissions tend to shorten and attacks lengthen over time, and the background ache tends to grow. The pain itself does not damage the nerve, and numbness or weakness mean something else is going on.
Carbamazepine is the first-line drug in both the American Academy of Neurology and the 2019 European Academy of Neurology guidelines, and it works unusually well: about 70 to 90 percent of people respond initially, with a number needed to treat of around 1.7. Oxcarbazepine is as effective and better tolerated. Both cause dizziness, drowsiness and low sodium, and carbamazepine needs a baseline blood count, liver tests and, in people of Asian ancestry, HLA-B*15:02 testing because of a severe skin reaction. Lamotrigine, baclofen, gabapentin and botulinum toxin injections are second-line add-ons. When drugs fail or become intolerable, surgery is offered. Microvascular decompression, which moves the offending vessel off the nerve, relieved pain immediately in 98 percent and kept about 70 percent of 1,185 patients pain-free at 10 years in the Pittsburgh series, with 0.2 percent mortality and about 1 percent risk of hearing loss. Percutaneous rhizotomy, balloon compression and Gamma Knife radiosurgery are less invasive and work in 70 to 90 percent initially, but pain returns in about half within 3 to 5 years, usually at the cost of facial numbness.
There is no supplement or herb that treats trigeminal neuralgia, and it would be unkind to pretend otherwise for a pain this severe. Topical capsaicin has a handful of tiny open-label reports, acupuncture has many low-quality trials from China that cannot be relied on, and feverfew, magnesium, omega-3, alpha-lipoic acid and B vitamins have no trials in TN at all. Where natural measures honestly fit is around the edges of drug treatment. Carbamazepine and oxcarbazepine are enzyme inducers that lower vitamin D levels and, over years, bone density, so checking and correcting vitamin D is sensible for long-term users. Vitamin B12 deficiency can cause facial neuropathic pain and is worth excluding with a blood test, particularly in older adults and anyone on metformin or acid suppressants. Beyond that, trigger management, a soft diet during clusters and a plan for breakthrough attacks do more than any capsule. Be wary of anything marketed as nerve repair for TN; the nerve is not the problem, the vessel pressing on it is.
The most common mistake is going to the dentist. Because the pain sits in the teeth and jaw, people with TN frequently have root canals and extractions, sometimes several, before anyone considers the nerve; the tooth comes out and the pain stays, which should be the clue. Dental pain is dull, throbbing and provoked by biting or temperature on one tooth; TN is a shock set off by light touch anywhere in the division. The second mistake is abandoning carbamazepine in the first week because of dizziness or nausea. Started low (100 mg twice daily) and raised every few days, most people tolerate it, and a slow-release formulation and a sodium check at 2 to 4 weeks solve most problems. The third is waiting too long for a surgical opinion: people who have had TN for fewer than about 7 years, who have typical paroxysmal pain and clear vascular contact on MRI, do best with microvascular decompression, and age alone is not a barrier.
At a Glance
- Common symptoms
- Sudden episodes of severe, shooting, or stabbing pain on one side of the face, Pain triggered by touching the face, chewing, speaking, brushing teeth, or wind, Episodes lasting from a few seconds to several minutes
- Main treatments
- Anticonvulsant medications (carbamazepine, oxcarbazepine) as first-line treatment, Baclofen or lamotrigine as adjunctive or alternative therapy, Microvascular decompression surgery to relieve nerve compression
- Category
- Neurological · Affects approximately 4-13 per 100,000 people annually
- See a doctor if
- You experience recurrent episodes of severe, electric shock-like facial pain
Symptoms
Causes
- Compression of the trigeminal nerve by a blood vessel (usually the superior cerebellar artery)
- Demyelination from multiple sclerosis damaging the trigeminal nerve sheath
- Tumor or arteriovenous malformation pressing on the trigeminal nerve
- Nerve damage from stroke, facial trauma, or surgical procedures
Risk Factors
- Age over 50 years
- Female sex
- History of multiple sclerosis
- High blood pressure (associated with vascular compression)
- Family history of trigeminal neuralgia (rare genetic component)
Diagnosis
- Detailed clinical history and neurological examination
- MRI of the brain to identify vascular compression, tumors, or multiple sclerosis plaques
- Magnetic resonance angiography (MRA) to visualize blood vessel-nerve relationships
- Electrophysiological testing of trigeminal reflexes in atypical cases
Treatment
- Anticonvulsant medications (carbamazepine, oxcarbazepine) as first-line treatment
- Baclofen or lamotrigine as adjunctive or alternative therapy
- Microvascular decompression surgery to relieve nerve compression
- Percutaneous procedures (radiofrequency rhizotomy, balloon compression, glycerol injection)
- Stereotactic radiosurgery (Gamma Knife) for patients unsuitable for open surgery
- Botox injections for refractory cases
Natural remedies for trigeminal neuralgia: what the evidence says
Ranked by the strength of human evidence for trigeminal neuralgia specifically. These sit alongside medical care, not in place of it.
Vitamin D
Moderate evidenceCarbamazepine and oxcarbazepine induce liver enzymes that break down vitamin D; long-term users have lower 25-hydroxyvitamin D levels and roughly double the fracture risk of the general population. In a 1-year randomized trial of 72 adults on enzyme-inducing antiseizure drugs, 4,000 IU of vitamin D a day improved bone density while 400 IU did not. This is a supportive measure for people on the drugs; it does nothing for the facial pain itself.
- Studied dose
- 1,000 to 2,000 IU of vitamin D3 daily, higher if a 25-hydroxyvitamin D level is below 20 ng/mL, rechecked after 3 months; ask about a bone density scan after several years on carbamazepine.
- Cautions
- Doses above 4,000 IU a day without blood tests can raise calcium; thiazide diuretics increase that risk. Correct a low level, do not chase a high one.
Vitamin B12
Preliminary evidenceVitamin B12 deficiency can cause burning or shooting facial and limb pain and is more common over 60, in vegans and in people on metformin or proton pump inhibitors. Case series describe trigeminal pain improving after B12 repletion in deficient patients, and small Asian trials of high-dose methylcobalamin injections report fewer attacks, but there is no placebo-controlled trial in TN and B12 does nothing for the vascular compression that causes classical disease. Ask for a B12 level (with methylmalonic acid if borderline) rather than taking it blind.
- Studied dose
- If deficient: 1,000 mcg oral cyanocobalamin or methylcobalamin daily, or injections if absorption is impaired, until the level normalizes.
- Cautions
- Very safe. High-dose B12 can turn urine bright yellow and rarely causes acne; it will not help if your level is normal.
Capsaicin
Preliminary evidenceTopical capsaicin depletes substance P in the skin and is approved as a patch for postherpetic neuralgia, which is why it is tried in TN. The evidence here is thin: an Italian series of 12 patients applying 0.025 percent cream three times daily for several weeks reported relief in 10, with recurrence in some after stopping, and no controlled trial has followed. Because applying anything to the face can trigger attacks, it is realistic only for people whose pain has a continuous component and whose skin tolerates touch.
- Studied dose
- 0.025 to 0.075 percent capsaicin cream applied thinly to the painful area 3 to 4 times daily for at least 4 weeks; burning on application usually fades after the first week.
- Cautions
- Wash hands after use and keep it away from the eyes, nose and mouth; the first applications can set off attacks. Do not combine with the 8 percent prescription patch, and stop if the skin blisters.
What matters day to day
- Map and manage your triggers rather than avoiding life: a scarf or face covering against wind and cold, lukewarm rather than hot or iced drinks, a straw placed on the unaffected side, and soft foods during clusters cut attack frequency without the weight loss and isolation that come from not eating or talking.
- Keep a simple attack diary (count, trigger, drug dose, sodium result): it shows your neurologist whether a dose change is working, and a rising count during a cluster is the signal to adjust early rather than endure.
- Never stop carbamazepine or oxcarbazepine abruptly: rebound attacks can be severe, and these drugs are tapered over weeks. Keep a few days' spare supply, and know that grapefruit juice raises carbamazepine levels.
- Protect your teeth with an extra-soft or electric toothbrush, warm water and a chlorhexidine rinse during flares: dental neglect during bad spells leads to real dental disease that muddies the picture and adds pain of its own.
- Tell your clinician if you feel hopeless: TN carries a real risk of depression and suicidal thoughts, treating the depression improves pain tolerance, and peer support through the Facial Pain Association helps many people.
- Review your other medicines with a pharmacist: carbamazepine speeds the breakdown of oral contraceptives, warfarin, many statins and some antidepressants, so doses and contraception may need changing.
Prevention
- No proven prevention, but avoiding known triggers can reduce attack frequency
- Protect the face from cold wind and drafts
- Eat soft foods and chew on the unaffected side during active episodes
- Manage underlying conditions such as multiple sclerosis and hypertension
When to See a Doctor
- You experience recurrent episodes of severe, electric shock-like facial pain
- Facial pain is not controlled by over-the-counter pain medications
- You develop new facial numbness, weakness, or other neurological symptoms
Frequently Asked Questions
References
- Bendtsen L, Zakrzewska JM, Abbott J, et al.. European Academy of Neurology guideline on trigeminal neuralgia. European Journal of Neurology (2019)
- Gronseth G, Cruccu G, Alksne J, et al.. Practice parameter: the diagnostic evaluation and treatment of trigeminal neuralgia (an evidence-based review). Neurology (2008)
- Cruccu G, Di Stefano G, Truini A. Trigeminal Neuralgia. New England Journal of Medicine (2020)
- Barker FG 2nd, Jannetta PJ, Bissonette DJ, et al.. The long-term outcome of microvascular decompression for trigeminal neuralgia. New England Journal of Medicine (1996)
- Wiffen PJ, Derry S, Moore RA, Kalso EA. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews (2014)
- Maarbjerg S, Di Stefano G, Bendtsen L, Cruccu G. Trigeminal neuralgia - diagnosis and treatment. Cephalalgia (2017)
- Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018)
- Morra ME, Elgebaly A, Elmaraezy A, et al.. Therapeutic efficacy and safety of Botulinum Toxin A therapy in trigeminal neuralgia: a systematic review and meta-analysis of randomized controlled trials. Journal of Headache and Pain (2016)
- Mikati MA, Dib L, Yamout B, et al.. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology (2006)
- National Institute of Neurological Disorders and Stroke. Trigeminal Neuralgia (2024)View source
Related Conditions
Have questions about Trigeminal Neuralgia?
Ask Mother Nature AI for personalized, evidence-based guidance.
Medical Disclaimer: This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.
Content reviewed against peer-reviewed medical literature and clinical guidelines. Read our editorial standards.